GSK and Google form partnership to develop bioelectronic medicinesBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4279 (Published 03 August 2016) Cite this as: BMJ 2016;354:i4279
- Gareth Iacobucci
- The BMJ
GlaxoSmithKline (GSK) has announced a new partnership with Google’s parent company, Alphabet, to carry out research into bioelectronic medicines.
GSK, the United Kingdom’s biggest drug company, will form a joint venture with Verily Life Sciences (formerly Google Life Sciences), a division of Alphabet. The joint venture, Galvani Bioelectronics, will focus on the research, development, and commercialisation of bioelectronic medicines. It will be 55% owned by GSK, and Verily will hold the remaining 45%.
The new company’s headquarters will be at GSK’s global research and development centre in Stevenage, UK. It will also operate a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial